Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REMS Reform Looks To Be Theme Of PDUFA V: Stakeholders Call For Standardization, Earlier Notice

Executive Summary

The biggest changes that came out of the FDA Amendments Act, the last round of Prescription Drug User Fee Act reauthorization, were FDA's augmented drug safety authorities, most specifically the Risk Evaluation and Mitigation Strategy tool. Going into the next round of PDUFA negotiations, a major focus will be on improving the implementation of the REMS program
Advertisement

Related Content

Everything REMS Under The Sun: FDA Lays Out Ambitious PDUFA V Meeting Agenda
"The Pink Sheet" – Most Notable Stories Of 2010
FDA Seeks Ways To Simplify REMS Modification Process
PDUFA Old School: Industry Wants User Fees To Get Back To Basics
Chart: FDA's Anticipated Timeline For Developing PDUFA V
Regulatory Updates, In Brief
Postmarket Industry Studies In Sentinel A Future Challenge, Woodcock Says
The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two
Sponsors Can Expect REMS Discussions As Early As Phase II, FDA Says
FDA “Safety First” Implementation: Drug Review, Drug Safety Offices To Meet Regularly

Topics

Advertisement
UsernamePublicRestriction

Register

PS052146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel